{
  "ticker": "JNJ",
  "target_date": "2025-03-12",
  "actual_date": "2025-03-12",
  "collected_at": "2025-12-08T11:30:27.955111",
  "price": {
    "open": 160.14,
    "high": 160.61,
    "low": 158.67,
    "close": 159.27793884277344,
    "volume": 8010700,
    "change_1d_pct": -1.81,
    "change_7d_pct": -2.65,
    "change_30d_pct": 9.16
  },
  "technicals": {
    "rsi_14": 56.83,
    "sma_20": 158.85,
    "sma_50": 149.85,
    "macd": 3.575,
    "macd_signal": 3.983,
    "macd_histogram": -0.409,
    "bb_upper": 167.65,
    "bb_lower": 150.04,
    "price_vs_sma20_pct": 0.27,
    "price_vs_sma50_pct": 6.29,
    "volume_ratio": 0.8
  },
  "fundamentals": {
    "market_cap": 489026682880,
    "pe_ratio": 19.592182,
    "forward_pe": 19.148584,
    "price_to_book": 6.1606526,
    "price_to_sales": 5.3069124,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.33,
    "pct_from_52w_low": 44.28
  },
  "macro": {
    "spy": {
      "price": 554.02,
      "change_1d_pct": 0.53,
      "change_7d_pct": -3.12
    },
    "vix": {
      "level": 24.23,
      "signal": "ELEVATED"
    },
    "treasury_10y": {
      "yield_pct": 4.32
    },
    "dollar_index": {
      "level": 103.61
    },
    "gold": {
      "price": 2939.1
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Why Johnson & Johnson (JNJ) is the Best Pharma Stock to Buy According to Hedge Funds",
      "source": "Yahoo",
      "datetime": 1741804014,
      "summary": "We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other best pharma stocks to buy according to hedge funds. Why is China the Talk of the Town in [\u2026]",
      "url": "https://finnhub.io/api/news?id=69a67d28f25787a36e848fa3c19962a31e24e6f183b1db9fd845cb5dc5a43eca"
    },
    {
      "headline": "Johnson & Johnson : 2025 Proxy Statement and additional solicitation materials (Johnson Johnson 2025 Proxy)",
      "source": "Finnhub",
      "datetime": 1741788012,
      "summary": "2025 Proxy Statement and Additional Definitive Proxy Solicitation Materials Definitive Proxy Statement, filed March 12, 2025 ...",
      "url": "https://finnhub.io/api/news?id=b1959e33189e69f08c2ecb71e923f3d09fd8dd831197c0e8c5302001cc3bca42"
    },
    {
      "headline": "Johnson & Johnson : Meeting agenda (2025 Meeting agenda)",
      "source": "Finnhub",
      "datetime": 1741788011,
      "summary": "Annual Shareholders Meeting April 24, 2025 Agenda Welcome 2024 Business Review ...",
      "url": "https://finnhub.io/api/news?id=7e62b462630aa1c7e37760ac208fd4a2100fabc8d461f8470a5614e1ff81d3ee"
    },
    {
      "headline": "Johnson & Johnson (JNJ): Among Dobermans of the Dow to Buy",
      "source": "Yahoo",
      "datetime": 1741787233,
      "summary": "We recently published a list of Dobermans of the Dow: 10 Stocks to Consider. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other Dobermans of the Dow to buy. The Dobermans of the Dow strategy serves as an alternative to the well-known Dogs of the [",
      "url": "https://finnhub.io/api/news?id=dd0b2104f844a45c1915f426e37c498508e1fce5856489d211fe78ede56c872f"
    },
    {
      "headline": "Caterpillar: Diversification Without Diworsification; Home Depot Looks Healthy, So Do Others",
      "source": "SeekingAlpha",
      "datetime": 1741786147,
      "summary": "Diversify Caterpillar holdings with tax-efficient strategies. Explore HD, LOW, and SNA for income replacement potential and strong dividend growth.",
      "url": "https://finnhub.io/api/news?id=9cf9ca56103d930886a81f4fb47de06448e6f9ac30502d33ccf692493d220c13"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-03-06",
      "description": "xslF345X05/wk-form4_1741297319.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000095/xslF345X05/wk-form4_1741297319.xml"
    },
    {
      "form": "4",
      "date": "2025-03-06",
      "description": "xslF345X05/wk-form4_1741297124.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000093/xslF345X05/wk-form4_1741297124.xml"
    },
    {
      "form": "4",
      "date": "2025-02-26",
      "description": "xslF345X05/wk-form4_1740613359.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000086/xslF345X05/wk-form4_1740613359.xml"
    },
    {
      "form": "8-K",
      "date": "2025-02-26",
      "description": "d863514d8k.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000119312525036773/d863514d8k.htm"
    },
    {
      "form": "8-K",
      "date": "2025-02-20",
      "description": "d866332d8k.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000119312525030851/d866332d8k.htm"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}